LY294002: Potent PI3K/Akt/mTOR Inhibitor for Cell Signaling Research

Executive Summary: LY294002 is a benchmark, cell-permeable inhibitor of class I PI3Ks, including p110α, p110β, and p110δ, with reversible and selective binding at the ATP-binding site (source: product_spec). At concentrations of 1–10 μM in cell culture, it inhibits PI3K/Akt/mTOR signaling, suppresses cell proliferation, and induces apoptosis and autophagy blockade (source: PI3K_inhibitor_review). LY294002 is distinguished by its operational reversibility and solubility in DMSO/ethanol, while being insoluble in water (source: product_spec). In vivo, daily intraperitoneal dosing at 100 mg/kg reduces tumor growth in OVCAR-3 xenograft mouse models (source: product_spec). The compound is supplied by APExBIO as a stable solid (SKU A8250) for cancer, fibrosis, and immunology research.

Biological Rationale

The phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway is a central regulator of cellular survival, proliferation, metabolism, and immune function. Dysregulation of this pathway is implicated in cancer, fibrotic diseases, and inflammatory conditions (source: Zhi-Chuan-Ling-asthma-study). Pharmacological inhibition of PI3K provides a precise tool to dissect pathway contributions in disease models. LY294002, a synthetic 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, enables specific, reversible blockade of class I PI3K isoforms, allowing controlled modulation of downstream Akt and mTOR effectors. This property is exploited in both oncology and immunology research to delineate mechanisms underlying cell survival, apoptosis, autophagy, and immune polarization.

Mechanism of Action of LY294002

LY294002 acts as a reversible, ATP-competitive inhibitor of class I PI3Ks, targeting the catalytic subunits p110α, p110β, and p110δ with IC₅₀ values of 0.5 μM, 0.97 μM, and 0.57 μM, respectively (source: product_spec). Upon binding, it prevents the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP₂) to phosphatidylinositol-3,4,5-trisphosphate (PIP₃), thus blocking activation of Akt and mTOR downstream (source: cancer_cell_signaling). This cascade interruption induces cell cycle arrest, promotes apoptosis, and inhibits autophagosome formation by reducing mTOR activity (source: PI3K_inhibitor_review). In addition, LY294002 demonstrates micromolar-range inhibition of BET bromodomain proteins (BRD2, BRD3, BRD4), expanding its utility for epigenetic and transcriptional studies (source: product_spec).

Evidence & Benchmarks

• LY294002 inhibits PI3K p110α with IC₅₀ = 0.5 μM, p110β with 0.97 μM, and p110δ with 0.57 μM, measured in vitro with purified enzyme assays (source: product_spec).
• In OVCAR-3 ovarian carcinoma xenograft mouse models, daily intraperitoneal administration at 100 mg/kg for 3 weeks resulted in significant reduction of tumor growth and cellularity (source: product_spec).
• In cell culture, LY294002 at 1–10 μM achieves dose-dependent suppression of cell proliferation, with cytotoxic effects observable after 24–72 hours (source: PI3K_inhibitor_review).
• LY294002 blocks autophagy by inhibiting autophagosome formation, as confirmed by LC3-II reduction in treated cell lines (source: cancer_cell_signaling).
• Compared to wortmannin, LY294002 is less potent but is more stable and reversible in aqueous/biological systems (source: product_spec).
• Solubility: insoluble in water, soluble in ethanol (≥13.55 mg/mL) and DMSO (≥15.37 mg/mL) at room temperature (source: product_spec).
• Recent work in allergic asthma models indicates PI3K/Akt/mTOR pathway inhibition suppresses M2 macrophage polarization and airway inflammation, suggesting broad utility for LY294002 in immunological studies (source: Zhi-Chuan-Ling-asthma-study).

This article extends the discussion in "LY294002: Potent PI3K Inhibitor Empowering Cancer Research" by providing a detailed protocol and new immunology-focused context.

It also clarifies benchmark solubility and reversibility data compared to "LY294002: Precision PI3K Pathway Inhibition in Fibrosis and Oncology", adding quantitative in vivo data.

For insight on fibrosis-specific PI3K modulation, see "MEG3 Regulates NiO NP-Induced Pulmonary Fibrosis via PI3K/AKT", which describes use of PI3K inhibitors for pathway validation in fibrotic models—a complementary angle not addressed in this review.

Applications, Limits & Misconceptions

LY294002 is widely used in oncology, immunology, and cell signaling studies. It is particularly valuable for dissecting PI3K/Akt/mTOR pathway contributions to cancer cell proliferation, apoptosis, autophagy, and immune polarization (source: Zhi-Chuan-Ling-asthma-study). The compound's reversibility allows for controlled, time-dependent inhibition, suitable for kinetic studies. However, its lack of water solubility necessitates careful preparation in DMSO or ethanol, and users should avoid storing solutions long-term (source: product_spec).

Common Pitfalls or Misconceptions

• LY294002 is not selective for class IA PI3K isoforms over class IB or other lipid kinases at high concentrations; off-target effects may occur (source: product_spec).
• Not suitable for clinical or therapeutic use; for research only as labeled by APExBIO (source: product_spec).
• Solutions in DMSO or ethanol are not stable for long-term storage, and freeze-thaw cycles reduce potency (source: product_spec).
• Inhibition of BET bromodomain proteins requires higher concentrations than required for PI3K inhibition (source: product_spec).
• LY294002 does not inhibit PI3K-independent pathways; negative results should not be overinterpreted as pathway exclusivity (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• in vitro PI3K inhibition assay | 0.5–1 μM | enzyme activity measurement | benchmark for class I PI3K selectivity | product_spec
• cell proliferation/apoptosis assay | 1–10 μM | cancer/immune cell lines | dose-dependent cytotoxicity and pathway inhibition | PI3K_inhibitor_review
• autophagy inhibition (LC3-II readout) | 10 μM | adherent cell models | blocks autophagosome formation via mTOR inhibition | cancer_cell_signaling
• in vivo tumor xenograft (OVCAR-3) | 100 mg/kg/day, i.p., 3 weeks | immunodeficient mice | reduces tumor volume and cellularity | product_spec
• solution preparation | DMSO/ethanol ≥13.5–15 mg/mL | all experimental formats | solubility requirement; avoid water | product_spec
• solution storage | use freshly prepared | all formats | avoid long-term storage to prevent degradation | product_spec

Conclusion & Outlook

LY294002 remains a foundational tool for dissecting the PI3K/Akt/mTOR axis and its roles in cancer, immunology, and fibrotic disease. Its reversible inhibition, well-characterized potency profile, and compatibility with multiple model systems enable reproducible, mechanistically grounded studies (source: product_spec). Ongoing research, including immunomodulatory models such as allergic asthma, further highlights the pathway’s centrality and the compound’s broad application. However, careful attention to dosing, solubility, and off-target effects is essential for robust experimental outcomes. For detailed product handling and ordering, refer to the APExBIO LY294002 page (A8250).